In our retrospective cohort, 17 (11.1%) women (age, 35 ± 5 years; gestational age, 32.6 ± 5.0 weeks; and weight gain, 7.9 ± 5.5 Kg) developed gestational hypertension and were treated with αMD at doses from 250 to 1000 mg/day. This evidence concerns the gene AMD1 and preeclampsia.